Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (211-220 of 504) with videos related to

Pageof 51
Sort By:
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
Leukemia & Lymphoma|September 17, 2013
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsChristopher B Benton, Farhad Ravandi, Michael Andreeff, et al.
Cell Cycle (Georgetown, Tex.)|June 5, 2012
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cellsJingxuan Pan, Chun Chen, Yanli Jin, et al.
Blood|June 9, 2016
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaSujan Piya, Steven M Kornblau, Vivian R Ruvolo, et al.
International Journal of Hematology|April 17, 2008
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-cateninJunya Kuroda, Yuri Kamitsuji, Shinya Kimura, et al.
British Journal of Haematology|July 26, 2002
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cellsMarina Konopleva, Shourong Zhao, Wei Hu, et al.
Cancer Research|May 21, 2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancerJer-Yen Yang, Chun-Ju Chang, Weiya Xia, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoidTianfu Wu, Yujin Ye, So-Youn Min, et al.
Plos One|October 7, 2015
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase ActivationGautam Borthakur, Seshagiri Duvvuri, Vivian Ruvolo, et al.
Research Square|March 4, 2025
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) PathwayAmnon Peled, Michal Abraham, Hanna Wald, et al.
Pageof 51

Showing results (211-220 of 504) with videos related to

Sort By:
Pageof 51
Haematologica|August 3, 2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine modelBing Z Carter, Po Yee Mak, Hong Mu, et al.
Leukemia & Lymphoma|September 17, 2013
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutationsChristopher B Benton, Farhad Ravandi, Michael Andreeff, et al.
Cell Cycle (Georgetown, Tex.)|June 5, 2012
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cellsJingxuan Pan, Chun Chen, Yanli Jin, et al.
Blood|June 9, 2016
Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemiaSujan Piya, Steven M Kornblau, Vivian R Ruvolo, et al.
International Journal of Hematology|April 17, 2008
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-cateninJunya Kuroda, Yuri Kamitsuji, Shinya Kimura, et al.
British Journal of Haematology|July 26, 2002
The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cellsMarina Konopleva, Shourong Zhao, Wei Hu, et al.
Cancer Research|May 21, 2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancerJer-Yen Yang, Chun-Ju Chang, Weiya Xia, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 23, 2014
Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoidTianfu Wu, Yujin Ye, So-Youn Min, et al.
Plos One|October 7, 2015
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase ActivationGautam Borthakur, Seshagiri Duvvuri, Vivian Ruvolo, et al.
Research Square|March 4, 2025
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) PathwayAmnon Peled, Michal Abraham, Hanna Wald, et al.
Pageof 51